Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD.
Phase of Trial: Phase II
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 23 May 2012 Results presented at the 108th International Conference of the American Thoracic Society.
- 19 May 2010 Actual patient number (51) added as reported by ClinicalTrials.gov.
- 19 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History